iSpecimen Inc. (NASDAQ:ISPC) Sees Significant Increase in Short Interest

iSpecimen Inc. (NASDAQ:ISPC) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totaling 305,108 shares, an increase of 2,171.8% from the November 30th total of 13,430 shares. Based on an average daily trading volume, of 364,222 shares, the days-to-cover ratio is currently 0.8 days. Approximately 3.6% of the shares of the company are sold short. Approximately 3.6% of the shares of the company are sold short. Based on an average daily trading volume, of 364,222 shares, the days-to-cover ratio is currently 0.8 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of iSpecimen to a “sell” rating in a research report on Saturday, September 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of iSpecimen in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Trading of iSpecimen

A hedge fund recently bought a new stake in iSpecimen stock. Scientech Research LLC acquired a new stake in iSpecimen Inc. (NASDAQ:ISPC) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned about 0.30% of iSpecimen at the end of the most recent reporting period. Hedge funds and other institutional investors own 13.62% of the company’s stock.

iSpecimen Stock Performance

NASDAQ:ISPC opened at $0.39 on Friday. The company has a market cap of $3.76 million, a price-to-earnings ratio of -0.05 and a beta of 1.80. iSpecimen has a fifty-two week low of $0.36 and a fifty-two week high of $3.38. The stock has a fifty day moving average price of $0.57 and a 200-day moving average price of $0.93.

iSpecimen (NASDAQ:ISPC) last posted its quarterly earnings results on Monday, November 17th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($3.80) by $3.32. iSpecimen had a negative return on equity of 531.78% and a negative net margin of 343.86%.The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $3.33 million.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.